Literature DB >> 21551478

Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections.

Hrafnhildur Stefansdottir1, Thor Aspelund, Vilmundur Gudnason, David O Arnar.   

Abstract

AIMS: Data are scarce on the epidemiology of atrial fibrillation (AF) in Europe. The aim of this study was to examine recent trends in the incidence and prevalence of AF and project the prevalence to the year 2050. METHODS AND
RESULTS: From 1991 to 2008 a total of 4905 residents of Reykjavik, Iceland were diagnosed with AF at the city's main health care centre. The age-standardized incidence of AF increased in women (0.9% per year, 95% CI 0.1-1.8) but not in men (0.1% per year, 95% CI -0.6 to 0.9). The age-standardized prevalence increased per year by 1.8% (95% CI 1.3-2.3) in men and 2.3% (95% CI 1.7-2.9) in women from 1998 to 2008. The number of adults with AF in Iceland is projected to increase from 4495 (prevalence 2.0%) in 2008 to 11 088 (prevalence 3.5%) in 2050, if the incidence of AF and mortality remain constant beyond 2008. However, if the incidence continues to increase as it has and mortality decreases according to projections for the general population, the projected number will rise to 13 583 (prevalence 4.3%).
CONCLUSION: In this study in a northern European population, the incidence of AF increased in women but not men from 1991 to 2008. The prevalence of AF is currently high and the number of patients with AF is expected to triple in the next four decades. AF is already a serious public health problem and the burden of this disease could reach epidemic proportions in the coming years.

Entities:  

Mesh:

Year:  2011        PMID: 21551478     DOI: 10.1093/europace/eur132

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  59 in total

Review 1.  Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta-analysis.

Authors:  Shadi Kalantarian; Hakan Ay; Randy L Gollub; Hang Lee; Kallirroi Retzepi; Moussa Mansour; Jeremy N Ruskin
Journal:  Ann Intern Med       Date:  2014-11-04       Impact factor: 25.391

2.  Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.

Authors:  Catharina Jm Klijn; Maurizio Paciaroni; Eivind Berge; Eleni Korompoki; Janika Kõrv; Avtar Lal; Jukka Putaala; David J Werring
Journal:  Eur Stroke J       Date:  2019-04-09

Review 3.  Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis.

Authors:  Darae Ko; Faisal Rahman; Renate B Schnabel; Xiaoyan Yin; Emelia J Benjamin; Ingrid E Christophersen
Journal:  Nat Rev Cardiol       Date:  2016-04-07       Impact factor: 32.419

Review 4.  Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps.

Authors:  Robert J Mentz; Lothar Roessig; Barry H Greenberg; Naoki Sato; Kaori Shinagawa; Daniel Yeo; Bernard W K Kwok; Eugenio B Reyes; Henry Krum; Burkert Pieske; Stephen J Greene; Andrew P Ambrosy; Jacob P Kelly; Faiez Zannad; Bertram Pitt; Carolyn S P Lam
Journal:  JACC Heart Fail       Date:  2016-06       Impact factor: 12.035

Review 5.  Management of atrial fibrillation in bradyarrhythmias.

Authors:  Giuseppe Boriani; Luigi Padeletti
Journal:  Nat Rev Cardiol       Date:  2015-03-17       Impact factor: 32.419

6.  A prospective study investigating the causes of warfarin under-utilization in Chinese patients.

Authors:  Shujuan Zhao; Hongwei Zhao; Xianpei Wang; Chuanyu Gao; Yuhua Qin; Haixia Cai; Boya Chen; Jingjing Cao
Journal:  Int J Clin Pharm       Date:  2016-08-03

7.  Vernakalant versus ibutilide for immediate conversion of recent-onset atrial fibrillation.

Authors:  I Vogiatzis; E Papavasiliou; I Dapcevitch; S Pittas; E Koulouris
Journal:  Hippokratia       Date:  2017 Apr-Jun       Impact factor: 0.471

8.  Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts.

Authors:  Hrafnhildur Stefansdottir; David O Arnar; Thor Aspelund; Sigurdur Sigurdsson; Maria K Jonsdottir; Haukur Hjaltason; Lenore J Launer; Vilmundur Gudnason
Journal:  Stroke       Date:  2013-02-26       Impact factor: 7.914

Review 9.  Prevention of stroke: a strategic global imperative.

Authors:  Valery L Feigin; Bo Norrving; Mary G George; Jennifer L Foltz; Gregory A Roth; George A Mensah
Journal:  Nat Rev Neurol       Date:  2016-07-22       Impact factor: 42.937

Review 10.  Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Authors:  Natalie J Carter; Greg L Plosker
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.